Platelet function testing and cardiovascular outcomes: Steps forward in identifying the best predictive measure

• References

• 1 Angiolillo DJ, Fernandez-Ortix A, Bernanrdo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives.. J Am Coll Cardiol 2007; 49: 1505-1516.
• 2 Smith Jr SC, Feldman TE, Hirshfeld Jr JW. et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention).. J Am Coll Cardiol 2006; 47: e1-121.
• 3 Yusuf S, Zhao F, Mehta SR. et al.; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.. N Engl J Med 2001; 345: 494-502.
• 4 Steinhubl SR, Berger PB, Mann JT. 3rd, et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO).. J Am Med Assoc 2002; 288: 2411-2420.
• 5 Sabatine MS, Cannon CP, Gibson CM. et al; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)- Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. CLARITY-TIMI 28 Investigators.. N Engl J Med 2005; 352: 1179-1189.
• 6 Chen ZM, Jiang LX, Chen YP. et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.. Lancet 2005; 366: 1607-1621.
• 7 Frere C, Cuisset T, Quilici J. et al. Determination of prognostic values of ADP-induced platelet aggregation and platelet reactivity index VASP for clinical outcomes in non-ST elevation acute coronary syndrome.. Thromb Haemost 2007; 98: 838-843.
• 8 Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection.. J Thromb Haemost 2007; 5 (Suppl. 01) 230-237.
• 9 Angiolillo DJ. ADP receptor antagonism: What’s in the pipeline?. Am J Cardiovasc Drugs 2007; in press.
• 10 Gurbel PA, Bliden KP, Guyer K. et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.. J Am Coll Cardiol 2005; 46: 1820-1826.
• 11 Angiolillo DJ, Bernardo E, Ramirez C. et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.. J Am Coll Cardiol 2007; in press.
• 12 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.. J Am Coll Cardiol 2006; 48: 1742-1750.
• 13 Cuisset T, Frere C, Quilici J. et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.. J Thromb Haemost 2006; 4: 542-549.
• 14 Cuisset T, Frere C, Quilici J. et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.. Thromb Haemost 2007; 97: 282-287.
• 15 Cuisset T, Frere C, Quilici J. et al. Benefit of a 60518-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.. J Am Coll Cardiol 2006; 48: 1339-1345.
• 16 Buonamici P, Marcucci R, Migliorini A. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.. J Am Coll Cardiol 2007; 49: 2312-2317.
• 17 Alfonso F, Angiolillo DJ. Platelet function assessment to predict outcomes after coronary interventions: hype or hope?. J Am Coll Cardiol 2006; 48: 1751-1754.
• 18 Angiolillo DJ, Shoemaker SB, Desai B. et al. A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease. Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study.. Circulation 2007; 115: 708-716.